Carna Biosciences, Inc. [4572.T]
TOKYO, May 08 (Pulse News Wire) – Carna Biosciences,inc. (4572.T) reported its fiscal 2026 first quarter consolidated results, which included significant non-operating expenses and special losses.
Operating expenses amounted to ¥13.2 million due primarily to interest payments related to convertible bonds and bond issuance costs. Additionally, the company recorded issuance fees of ¥11.2 million associated with the issuance of subscription warrants for docirbrutinib development promotion on February 17, 2026. Foreign exchange fluctuations led to a foreign exchange loss of ¥7.4 million.
Furthermore, the company incurred a debt extinguishment loss of ¥20.1 million following the repurchase and cancellation of its first unsecured convertible bond on February 17, 2026. A reduction in asset value also resulted in impairment losses totaling 3,006 thousand yen. These factors contributed to the overall impact reflected in the company's first quarter earnings statement released today.
The detailed financial figures are available in the "2026 December Term First Quarter Condensed Financial Results [Japanese Standards] (Consolidated)." For further inquiries, shareholders and investors should.
🟢 Confidence: High AI-translated content.